Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

10-12-2020 | SABCS 2020 | Conference coverage | Video

Biomarker data point to wide use of sacituzumab govitecan in advanced TNBC

Sara Hurvitz discusses additional results from the ASCENT study showing favorable outcomes with sacituzumab govitecan in patients with metastatic triple-negative breast cancer regardless of biomarker status (5:24).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript
Image Credits